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1105-176 Effect of Black Tea on Aortic Stiffness
Charalambos Vlachopoulos, Nikolaos Alexopoulos, Foteini Kosmopoulou, Dorothea 
Tsekoura, Georgios Papadopoulos, Konstantina Aggeli, Constantinos Stratos, Christos 
Pitsavos, Christodoulos Stefanadis, Athens Medical School, Athens, Greece, Henry 
Dynant Hospital, Athens, Greece
Background: We have shown that caffeine increases acutely arterial stiffness. Tea is a
widely consumed beverage, however, its effect on arterial stiffness has not been defined.
Aortic stiffness is an important prognosticator of cardiovascular risk.
Methods: We studied 12 healthy volunteers (33±5 years) in a randomized, single-blind,
crossover fashion. The subjects were studied on 3 separate occasions: a) 6 gr of black
tea, b) 175 mg of caffeine alone (the amount contained in 6 gr of tea) and c) placebo.
Carotid-femoral pulse wave velocity (PWV) was measured as an index of aortic stiffness
using a validated automated, non-invasive device (Complior®).
Results: Tea had a biphasic effect on aortic stiffness. Initially it led to a marginal
(P=0.07) increase in PWV, which, however, rapidly disappeared. In contrast, caffeine
alone led to a sustained increase in PWV (P<0.05, figure). The reversal of aortic stiffness
increase with tea after the initial 30 minutes can be attributed to a beneficial effect of tea
flavonoids that peak later than caffeine. Pressures were increased in a similar manner
both with tea and caffeine (systolic: by 8.8 and 7.8 mmHg respectively, P<0.001 for both).
Conclusions: Tea shows a tendency to increase initially aortic stiffness due to the caf-
feine that it contains. However, this effect is promptly counterbalanced by a beneficial
effect of tea flavonoids. This finding provides valuable insights for the effects of tea con-
sumption on the cardiovascular system. 
1105-178 Preservation of Brachial Artery Endothelial Function in 
Otherwise Healthy Patients With Obstructive Sleep 
Apnea
Maria E. Otto, Rodrigo Bellio Barretto, Anna Svatikova, Simone Santos, Kevin A. Bybee, 
Bijoy Khandheria, Virend K. Somers, Mayo Clinic, Rochester, MN
Background: Obstructive sleep apnea (OSA) has been implicated in several cardiovas-
cular disease conditions including hypertension, heart failure and cerebrovascular dis-
ease. Impaired endothelial function is thought to be involved in risk for future
cardiovascular disease in OSA. We tested the hypothesis that otherwise healthy OSA
patients, in the absence of any confounding factors, have impaired brachial artery endot-
helial function.
Methods: We studied 16 newly diagnosed, never treated OSA patients (age: 44.7±3.7
years; apnea-hypopnea index: 45±10 events/hour) and 16 matched normal controls
(age: 43.4 ± 2.7 years; apnea-hypopnea index: 2±4 events/hour). All subjects were on no
medications and free of any other diseases. None of the subjects smoked and both
patients and controls had similar body mass index, blood pressure, fasting glucose and
plasma lipids. Control subjects underwent complete polysomnography to exclude occult
OSA. Conduit-vessel endothelial function was evaluated by high-resolution ultrasound of
the brachial artery. Brachial artery diameter was measured at baseline and after five min-
utes of ischemia induced by cuff inflation as a measure of endothelium-dependent
vasodilation, and after sublingual administration of nitroglycerin, endothelium-indepen-
dent vasodilation.
Results: Data are presented as mean ± standard error. Baseline brachial artery diame-
ters were similar in OSA and control subjects (4.34 ± 0.1 mm in OSA and 4.04 ± 0.1 mm
in controls; p= 0.12). Percent changes of brachial artery diameter in reponse to ischemia
were similar in both groups (7.0 ± 0.8% in OSA vs 6.5 ± 1.3 in controls; p=0.73). Percent
changes of brachial artery diameter to nitroglycerin were also similar in both groups (15.0
± 1.8% in OSA vs 15.3 ± 1.3% in controls; p=0.91), thus confirming the absence of struc-
tural abnormalities of conduit-vessels in OSA patients.
Conclusions: We conclude that in otherwise healthy patients with OSA, in the absence
of potential confounding factors that would affect measurements of brachial artery endot-
helial function, there is no evidence of impaired endothelial function in conduit-vessels.
1105-179 Influence of Coenzyme Q10 and Cerivastatin on the 
Flow-Mediated Vasodilation of the Brachial Artery: 
Results of the ENDOTACT Study
Stephen Schroeder, Axel Kuettner, Torsten Beck, Thomas Athanasiou, Christof 
Burgstahler, Juergen Koch, Franz Enzmann, Christian Herdeg, University of Tuebingen, 
Tuebingen, Germany
Aim: Endothelial dysfunction (ED) is the functional prestep in atherosclerosis. Different
studies could show a positive effect of statins on ED. Coenzyme Q10 (CoQ10) is known
as a potent natural antioxidant which is part of mammalian mitochondria. Since the pro-
duction of CoQ10 under physiological conditions is HMG-CoA-Reductase dependent, an
effect of statin therapy on CoQ10 levels is discussed. Aim of the present study was to
evaluate the effects of CoQ10 on ED of the brachial artery, and the influence of statin
therapy on plasma CoQ10 levels.
Methods and Results: 25 male patients with manifest ED (flow-mediated vasodilation
[FMD%] < 4.5%) were included in this prospective, randomized, cross-over study. ED of
the brachial artery was assessed by the use of high-resolution ultrasound. Each patient
had to pass through three treatment phases in a randomized order (1: single therapy with
cerivastatin (C), 2: single therapy with CoQ10, 3: combination therapy). FMD% signifi-
cantly improved throughout all treatment phases (1: 3.50 ± 4.05% vs 8.80 ± 6.39%,
p=0.009; 2: -0.25 ± 4.0% vs 7.06% ± 4.39%, p=0.004; 3: 3.14 ± 3.54% vs 8.82 ± 5.78%,
p=0.011). C led to a significant decrease of CoQ10 plasma levels (1.23 ± 0.34 vs 0.87 ±
0.39 µg/ml, p=0.004).
Conclusion: Our results indicate a positive influence of CoQ10 supplementation on
human ED, which appears to be independent of lipid-lowering and comparable to statin
therapy. In addition, statin therapy lowered CoQ10 plasma levels. The pathophysiological
relevance of this finding remains, however, unclear. Although large-scale studies evaluat-
ing other antioxidants failed to demonstrate a positive prognostic effect, CoQ10 has
never been evaluated in larger trials. Experimental as well as our clinical results indicate
that CoQ10 warrants further attention in atherosclerosis research.
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1106-177 Pharmacokinetics of Clopidogrel and Its Active 
Metabolite in Human Plasma
Stephanie Harlfinger, Reinhard Berkels, Dirk Taubert, Nicolas von Beckerath, Olga 
Gorchakova, Adnan Kastrati, Albert Schömig, Edgar Schömig, University of Cologne, 
Cologne, Germany, Deutsches Herzzentrum, Technische Universitat Munchen, Munich, 
Germany
Background: Clopidogrel an ADP receptor antagonist is an inactive prodrug that is con-
verted into both an active metabolite (2-{1-[1-82-chlorophenyl)-2-oxoethyl]-4-sulfanyl-3-
piperidinylidene}acetic acid) and an inactive carboxy metabolite (SR26334) in the liver.
So far, there are only data available regarding the pharmacokinetics of the inactive
metabolite. The plasma kinetics of clopidogrel have not yet been elucidated and the
active metabolite has not been measured in vivo so far. We developed a method to deter-
mine the plasma concentrations of clopidogrel and its active metabolite after a loading
dose of 600 mg clopidogrel.
Methods: Ten healthy volunteers (9 men, 1 women, age 25 – 48) received a single oral
dose of 600 mg clopidogrel. Plasma was collected predose and at 0.5; 1; 1.5; 2; 3; 6 and
9 hours postdose. After protein precipitation with acetonitrile the concentrations of clopi-
dogrel, the carboxy metabolite, and the active metabolite were measured by LC-ESI-MS/
MS (TSQ Quantum Thermo Finnigan).
Results: Cmax, tmax and t1/2 (mean ± SEM) plasma concentrations of clopidogrel were
42.55 ng/ml ± 11.24; 1.45 h ± 0.27 and 1.6 h ± 0.13. Tmax and t1/2 were 1.65 h ± 0.23
and 3.23 h ± 0.17 for the carboxy metabolite. The plasma concentrations of the active
metabolite of clopidogrel were correlated with clopidogrel plasma concentrations (r =
0.575; p < 0.001; n = 87). Diltiazem (1 µg/ml) was used as internal standard.
Conclusions: This is the first report of the pharmacokinetics of clopidogrel and its active
metabolite in human plasma. Measurement of clopidogrel and metabolite plasma con-
centrations may lead to a deeper understanding of clopidogrel resistance.
1106-180 Negative Inotropic Effect of Selective AT2 Receptor 
Stimulation and Its Modulation by Endocardial 
Endothelium, Nitric Oxide and Prostaglandins
Adelino F. Leite-Moreira, Susana S. Soares, Alexandre Lima-Carneiro, Paulo Castro-
Chaves, Faculty of Medicine, Porto, Portugal
Introduction: Angiotensin II (AT-II) is an endogenous peptide whose effects are medi-
ated by two types of receptors, AT1 and AT2. AT1 receptors are responsible for the vaso-
constrictor, positive inotropic and growth promoting properties of AT-II, while AT2
receptors have been linked to vasodilator and anti-mitogenic properties. In this study we
investigated the effects of selective AT2 receptor stimulation on myocardial contractility,
which are not yet known. Methods: Effects of selective AT2 receptor activation were
evaluated in rabbit right papillary muscles (n=35) by adding, to the superfusing solution
(Krebs-Ringer; 1.8mM CaCl2; 35ºC), increasing doses of AT-II (10-8, 10-7, 10-6, 10-5 M) in
the presence of a selective AT1 receptor antagonist (ZD7155, 10-6 M). Effects of selec-
